Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F18 FBPA (4-Borono-2-[18F]fluoro-L-phenylalanine) is a radiolabeled phenylalanine analog used as a diagnostic imaging agent in positron emission tomography (PET). It is specifically designed to target the L-type amino acid transporter 1 (LAT1), which is frequently overexpressed in various malignant solid tumors. By mimicking a natural amino acid, the tracer accumulates preferentially in tumor cells, allowing for high-contrast visualization of tumor distribution and metabolic activity. Heron Neutron Medical Corp. is developing this agent to evaluate its safety and diagnostic performance in patients with solid tumors, particularly to assist in screening and treatment planning for Boron Neutron Capture Therapy (BNCT).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-borono-2-[18F]fluoro-L-phenylalanine.